ATE102022T1 - Zusammensetzung zur kontrollierten abgabe von medikamenten. - Google Patents

Zusammensetzung zur kontrollierten abgabe von medikamenten.

Info

Publication number
ATE102022T1
ATE102022T1 AT91114374T AT91114374T ATE102022T1 AT E102022 T1 ATE102022 T1 AT E102022T1 AT 91114374 T AT91114374 T AT 91114374T AT 91114374 T AT91114374 T AT 91114374T AT E102022 T1 ATE102022 T1 AT E102022T1
Authority
AT
Austria
Prior art keywords
composition
medications
controlled delivery
macromolecular compound
drug
Prior art date
Application number
AT91114374T
Other languages
English (en)
Inventor
Yasushi Morita
Akira Ohtori
Masako Andoh
Original Assignee
Senju Pharma Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Senju Pharma Co filed Critical Senju Pharma Co
Application granted granted Critical
Publication of ATE102022T1 publication Critical patent/ATE102022T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1635Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1641Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647Polyesters, e.g. poly(lactide-co-glycolide)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2031Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/204Polyesters, e.g. poly(lactide-co-glycolide)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007Drug-containing films, membranes or sheets

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
AT91114374T 1990-08-30 1991-08-27 Zusammensetzung zur kontrollierten abgabe von medikamenten. ATE102022T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP22988790 1990-08-30

Publications (1)

Publication Number Publication Date
ATE102022T1 true ATE102022T1 (de) 1994-03-15

Family

ID=16899272

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91114374T ATE102022T1 (de) 1990-08-30 1991-08-27 Zusammensetzung zur kontrollierten abgabe von medikamenten.

Country Status (10)

Country Link
US (1) US5183662A (de)
EP (1) EP0474098B1 (de)
JP (1) JP3934684B2 (de)
KR (1) KR970009579B1 (de)
AT (1) ATE102022T1 (de)
CA (1) CA2050067C (de)
DE (1) DE69101291T2 (de)
DK (1) DK0474098T3 (de)
ES (1) ES2062634T3 (de)
RU (1) RU2053769C1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA932272B (en) * 1992-03-30 1993-10-19 Alza Corp Viscous suspensions of controlled-release drug particles
US5626862A (en) 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
US5869079A (en) 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
FR2748205A1 (fr) * 1996-05-06 1997-11-07 Debio Rech Pharma Sa Compositions pharmaceutiques pour la liberation controlee de principes actifs insolubles
ES2221019T3 (es) 1996-10-31 2004-12-16 Takeda Chemical Industries, Ltd. Preparacion de liberacion mantenida.
KR100244164B1 (ko) * 1997-07-15 2000-03-02 김용옥 수용성 고분자-타크로리무스 접합체 화합물 및 그의 제조 방법
US6498153B1 (en) 1998-12-31 2002-12-24 Akzo Nobel N.V. Extended release growth promoting two component composition
JP2000281561A (ja) * 1999-03-26 2000-10-10 Ajinomoto Co Inc 新規溶媒法固体分散体製剤
US6726918B1 (en) 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
DE10058772A1 (de) * 2000-11-27 2002-06-06 Falk Pharma Gmbh Verfahren zur Herstellung leicht löslicher Arzneimittelformulierungen und entsprechende Formulierungen
AU2002236495B2 (en) 2000-11-29 2006-05-11 Allergan, Inc. Intraocular implants for preventing transplant rejection in the eye
KR100446101B1 (ko) * 2000-12-07 2004-08-30 주식회사 삼양사 수난용성 약물의 서방성 제형 조성물
CA2451187C (en) 2001-06-22 2012-08-14 Southern Biosystems, Inc. Zero-order prolonged release coaxial implants
WO2003075892A1 (en) * 2002-03-13 2003-09-18 Novartis Ag Pharmaceutical microparticles
WO2003077883A2 (de) * 2002-03-15 2003-09-25 Kuyus Stiftung Zusammensetzung und verwendung derselben zur bildung eines schutzfilms auf nasenschleimhäuten
US20050048099A1 (en) 2003-01-09 2005-03-03 Allergan, Inc. Ocular implant made by a double extrusion process
PE20050150A1 (es) 2003-05-08 2005-03-22 Altana Pharma Ag Una forma de dosificacion que contiene (s)-pantoprazol como ingrediente activo
CL2004000983A1 (es) 2003-05-08 2005-03-04 Altana Pharma Ag Composicion farmaceutica oral en forma de tableta que comprende a pantoprazol magnetico dihidratado, en donde la forma de tableta esta compuesto por un nucleo, una capa intermedia y una capa exterior; y uso de la composicion farmaceutica en ulceras y
MY142989A (en) 2004-03-10 2011-02-14 Bayer Schering Pharma Ag Stabilised supersaturated solids of lipophilic drugs
US20050244469A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
JP2008533204A (ja) * 2005-03-21 2008-08-21 マクサイト, インコーポレイテッド 病気又は症状の治療のためのドラッグ送達システム
US20070106271A1 (en) * 2005-11-09 2007-05-10 Searete Llc, A Limited Liability Corporation Remote control of substance delivery system
US8802128B2 (en) 2006-06-23 2014-08-12 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
KR100816065B1 (ko) * 2006-11-27 2008-03-24 동국제약 주식회사 초기 방출억제 특성이 우수한 서방출성 마이크로캡슐의제조방법 및 이에 의해 제조되는 마이크로캡슐
KR100871988B1 (ko) 2007-06-25 2008-12-05 한국과학기술원 수용성 용매 없이 수용성 거대분자 약물이 봉입된 생분해성미립구 담체의 제조방법 및 생분해성 미립구 담체
US10064819B2 (en) 2008-05-12 2018-09-04 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
JP5591226B2 (ja) 2008-05-12 2014-09-17 ユニバーシティ・オブ・ユタ・リサーチ・ファウンデイション 眼内薬物送達装置および関連する方法
US9877973B2 (en) 2008-05-12 2018-01-30 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US9095404B2 (en) 2008-05-12 2015-08-04 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
GB201119985D0 (en) * 2011-11-19 2012-01-04 Diurnal Ltd Treatment of adrenal insufficiency
US10806703B2 (en) * 2012-01-20 2020-10-20 Lts Lohmann Therapie-System Ag Transmucosal administration system for a pharmaceutical drug
GB201308933D0 (en) 2013-05-17 2013-07-03 Diurnal Ltd Paediatric composition

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1391554A (en) * 1972-08-03 1975-04-23 Beecham Group Ltd Pharmaceutical compositions and process for their preparation
US4048256A (en) * 1976-06-01 1977-09-13 American Cyanamid Company Normally-solid, bioabsorbable, hydrolyzable, polymeric reaction product
WO1978000011A1 (fr) * 1977-06-07 1978-12-21 Garching Instrumente Forme d'implant medicamenteux et procede de preparation
GB2091554B (en) * 1981-01-13 1984-09-12 Mitsui Toatsu Chemicals Rod like moulded drug
US4432964A (en) * 1981-08-24 1984-02-21 Alza Corporation Topical composition containing steroid in two forms released independently from polymeric carrier
US4666704A (en) * 1985-05-24 1987-05-19 International Minerals & Chemical Corp. Controlled release delivery system for macromolecules
US4741872A (en) * 1986-05-16 1988-05-03 The University Of Kentucky Research Foundation Preparation of biodegradable microspheres useful as carriers for macromolecules

Also Published As

Publication number Publication date
JPH054924A (ja) 1993-01-14
ES2062634T3 (es) 1994-12-16
CA2050067A1 (en) 1992-03-01
EP0474098A1 (de) 1992-03-11
JP3934684B2 (ja) 2007-06-20
DE69101291D1 (de) 1994-04-07
EP0474098B1 (de) 1994-03-02
CA2050067C (en) 2000-05-30
KR970009579B1 (ko) 1997-06-14
KR920003973A (ko) 1992-03-27
US5183662A (en) 1993-02-02
DE69101291T2 (de) 1994-07-07
DK0474098T3 (da) 1994-05-02
RU2053769C1 (ru) 1996-02-10

Similar Documents

Publication Publication Date Title
DE69101291D1 (de) Zusammensetzung zur kontrollierten Abgabe von Medikamenten.
ATE208612T1 (de) Biologisch erodierbare vorrichtung zur verabreichung von wirkstoffen
DE3778244D1 (de) Oestradiol-implantat und verfahren zu seiner herstellung.
DE68907139D1 (de) Mikrokapsel mit verzoegerter freigabe fuer wasserloesliche arzneistoffe.
DE69022876D1 (de) Arzneimittelformulierungen mit verzögerter Wirkstoffabgabe.
YU46701B (sh) Postupak u za dobijanje osnovnog nosećeg materijala za dozne oblike lekova sa produženim izdvajanjem aktivne supstance
ATE133862T1 (de) Arzneimittel mit verzögerter freigabe
DK0436217T3 (da) Antiinflammatorisk analgetisk plaster
ATE101035T1 (de) Implantierbares, biologisch abbaubares wirkstofffreigabesystem.
DE69128621D1 (de) Biokeramisches system zur abgabe von bioaktiven stoffen
DE59009351D1 (de) Neue arylpyridazine, ihre herstellung, verwendung und sie enthaltende arzneimittel.
NO954582D0 (no) Blanding for nasal administrering av nikotin
DE69832631D1 (de) Zusammensetzungen geeignet zur kontrollierten freisetzung des hormons gnrh und dessen analoga
NO900356L (no) Blandinger med forsinket frigjoering.
GR3030732T3 (en) Pharmaceutical compositions including a drug, a cross-linked polymeric substance, an oil, and a surface active agent.
ATE198152T1 (de) Oral anzuwendende arzneizubereitung mit verzögerter wirkstoffabgabe
DE69840908D1 (de) Zusammensetzung von prostaglandin-i-derivaten mit verzoegerter abgabe
DK0400522T3 (da) Fremgangsmåde til fremstilling af mikroniserede bionedbrydelige partikler
ES2058149T3 (es) 3,4-dihidro-2h-benzopiranos sustiuidos, procedimiento para su preparacion, su empleo, asi como preparados farmaceuticos a base de estos compuestos.
SE9403389D0 (sv) Pharmaceutical composition containing derivattves of sex hormones
ATE83668T1 (de) Pflaster zur transdermalen anwendung.
NO883520D0 (no) Fremgangsmaate for fremstilling av et injeksjonspreparat.
DE59107240D1 (de) Emulgatorfreie Emulsionspolymere in pharmazeutischen Zubereitungen mit verzögerter Wirkstofffreigabe und ihre Herstellung
DK0426098T3 (da) Fremstilling af et lægemiddel til behandling af hyperphosphatæmisk status
EP0348664A3 (de) Monoacetoacetine enthaltende pharmazeutische Zusammensetzungen zur Behandlung von Tumoren

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee